The Oncology Institute, Inc. (STLN) Stock Price & Analysis
The Oncology Institute, Inc. (STLN) closed at USD 6.64 on Wednesday, October 28, 2026, up 0.76% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 6.59; the Oct 28, 2026 session ranged USD 6.5–6.79 on volume of 1,143,439 shares. Market capitalization is $676.72M, with a 52-week range of USD 2.32–7.13 (NCM). Source: Nexqual, retrieved October 29, 2026 at 06:21 UTC.
Also available as compact Markdown for AI agents: nexqual.com/STLN.md
Key facts (STLN)
- Last four reported quarters (through Jun 30, 2026): revenue $587M, net income -$36.3M (-6.2% margin), free cash flow -$3.3M (SEC filings).
- Analysts: Buy (mean 1.80 on a 1–5 scale) (5 analysts), mean target USD 9.4 (range 8–11).
- Total return with dividends: 1Y +41.3% vs S&P 500 +13.6%; 5Y -33.6% vs S&P 500 +79.8%.
- Next earnings: 2026-11-05, EPS estimate USD -0.05, revenue estimate $169M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (STLN)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $203M | $252M | $324M | $393M | $503M | $587M |
| Operating income | -$45.9M | -$82.0M | -$77.0M | -$60.1M | -$36.1M | -$26.1M |
| Net income | -$10.9M | $152K | -$83.1M | -$64.7M | -$60.6M | -$36.3M |
| EPS (diluted) | -$0.16 | -$0.21 | -$0.92 | -$0.71 | -$0.54 | — |
| Free cash flow | -$35.5M | -$67.3M | -$40.9M | -$30.3M | -$27.8M | -$3.3M |
| Operating margin | -22.6% | -32.5% | -23.8% | -15.3% | -7.2% | -4.4% |
| Net margin | -5.4% | 0.1% | -25.6% | -16.4% | -12.1% | -6.2% |
| Revenue growth | +8.3% | +24.4% | +28.4% | +21.3% | +27.8% | — |
| Cash + short-term investments | $115M | $73.8M | $82.9M | $49.7M | — | — |
| Total debt | $183K | $80.6M | $86.8M | $93.1M | $77.4M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (STLN)
P/S 1.1x · FCF yield -0.49% · Earnings yield -5.36%
Analysts (STLN)
Consensus Buy (mean 1.80 on a 1–5 scale), 5 analysts; mean target USD 9.4 (low 8, high 11).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-14 | Needham | Target raised | Buy | $7 → $9 |
| 2026-07-09 | BTIG | Target raised | Buy | $8 → $9 |
| 2026-07-06 | Lake Street | Initiated | Buy | $10 |
Total return (dividends reinvested) (STLN)
| 1Y (from 2025-10-29) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | +41.3% | -33.6% |
| S&P 500 (SPY) | +13.6% | +79.8% |
| Per year | +41.4% | -7.8% |
| Volatility (annualized) | 77.7% | 118.2% |
| Max drawdown | -49.3% (Oct 2025→Feb 2026) | -98.6% (Nov 2021→Nov 2024) |
STLN earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | −$0.08 | −$0.06 | Miss −33.3% | — |
| — | Quarter ended Mar 31, 2026 | −$0.02 | −$0.09 | Beat +77.8% | — |
| — | Quarter ended Dec 31, 2025 | −$0.06 | −$0.09 | Beat +33.3% | — |
| — | Quarter ended Sep 30, 2025 | −$0.14 | −$0.11 | Miss −27.3% | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
STLN recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Sep 2, 2026 | 8-K | Director or executive officer change, or pay arrangement “On September 1, 2026, Brad Hively notified Starling Oncology, Inc. (the "Company") of his decision to not stand for re-election to the Board of the Directors of the Company (the "Board") at its 2027 annual meeting of stockholders (the "Annual Meeting"). Mr. Hively is expected to continue to serve as a director of the Company until the Annual Meeting, but effective immediately, will no longer serve as Vice Chairman of the Board or as a member of the Compliance Committee or any other committees of the Board. Mr.…” |
| Aug 21, 2026 | 8-K | Entered a material agreement; New debt or off-balance-sheet obligation “On August 20, 2026, Starling Oncology Management, Limited Liability Company, a wholly owned subsidiary of Starling Oncology, Inc. ("SOM, LLC"), entered into a Credit Agreement (the "Revolving Loan Agreement") among SOM, LLC, such other persons joined thereto as a borrower from time to time, and Gemino Healthcare Finance, LLC d/b/a SLR Healthcare ABL, as lender. The Revolving Loan Agreement provides access to a revolving line of credit facility in the aggregate principal amount of up to $25 million (the "Revolving…” |
| Aug 6, 2026 | 10-Q | Quarterly report · period ended Jun 30, 2026 |
| Aug 6, 2026 | 8-K | Quarterly results |
| Aug 3, 2026 | 8-K | Bylaws or fiscal-year change; Regulation FD disclosure |
| Jul 7, 2026 | 8-K | Entered a material agreement; New debt or off-balance-sheet obligation; Unregistered sale of shares; Regulation FD disclosure “Term Loan Agreement On July 1, 2026, The Oncology Institute, Inc. (the "Company") entered into a Credit Agreement (the "Term Loan Agreement"), by and among the Company, the lenders from time to time party thereto, and Orbimed Opportunities (CA) V LLC, as the initial lender and administrative agent. The Term Loan Agreement provides for a term loan facility in an aggregate principal amount of $75 million, which was drawn in full on the date of entry into the Term Loan Agreement (the "Closing Date"). Loans under the…” |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
STLN revenue by business segment (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Specialty pharmacy | $98.6M | 61.1% | +57.6% |
| Patient services | $58.8M | 36.5% | +5.3% |
| Clinical trials & other | $3.8M | 2.4% | +187.5% |
| Total revenue | $161.3M | 100% | — |
STLN revenue by product line (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Specialty Pharmacy | $98.6M | 61.1% | +57.6% |
| Patient services | $58.8M | 36.5% | +5.3% |
| — FFS revenue (part of Patient services) | $30.9M | 19.1% | -16.7% |
| — Capitated revenue (part of Patient services) | $28.0M | 17.3% | +48.5% |
| Clinical trials & other | $3.8M | 2.4% | +187.5% |
| Total revenue | $161.3M | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
STLN suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | The Oncology Institute | “While we continue our original purpose of seeing our patients on a fee-for-service basis for their oncology, hematology, specialty infusion, oral pharmacy needs, as well as enrolling patients in clinical trials, where appropriate, TOI's true mission lies in our differentiated ability to partner with managed care providers and other risk-bearing entities to transfer the risk and patient coordination responsibility …” |
| Partner | Helios CR | “(1) During the year ended December 31, 2025, non-cash addbacks was comprised of the write-off of the net assets of the Clinical Trials segment and certain expenses incurred through our shared services agreement with Helios of $2,398 and a bad debt write off of $2,594, offset by non-cash rent expense of $665.” |
Quoted from the company's 10-K filed Mar 12, 2026.
STLN customer concentration
In the period ended Jun 30, 2026, 2 direct customers each accounted for at least 10% (13%, 12%) of revenue, per the company's 10-Q filed Aug 6, 2026. The company does not name them.
STLN company outlook (results filed Aug 6, 2026)
- “(NASDAQ: STLN) (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its quarter ended June 30, 2026 and updated it's full-year 2026 guidance.”
Quoted word-for-word from the SEC 8-K results press release.
STLN analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.05 | $-0.04 | −$0.01 | $168.7M | 5 |
| Next quarter (ends Dec 2026) | $-0.01 | $-0.02 | $0.00 | $187.7M | 5 |
| Current fiscal year (ends Dec 2026) | $-0.16 | $-0.14 | −$0.02 | $665.0M | 5 |
| Next fiscal year (ends Dec 2027) | $0.00 | $-0.03 | +$0.03 | $884.0M | 4 |
Key Statistics (as of October 29, 2026 at 06:21 UTC)
| Price | USD 6.64 |
|---|---|
| Change | ▲ 0.76% (up) |
| Previous Close | USD 6.59 |
| Open | USD 6.62 |
| Day Range | USD 6.5 – 6.79 |
| 52-Week Range | USD 2.32 – 7.13 |
| Volume | 1,143,439 shares |
| Market Cap | $676.72M |
| Exchange | NCM |
Technical Analysis (STLN)
Nexqual's technical model rates STLN "STRONG BUY" based on 5 bullish and 0 bearish signals across 127 daily candles, as of October 29, 2026 at 06:21 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 52.54 (neutral) |
| vs SMA50 | Above (USD 6.47) |
| MACD | 0.05 (positive) |
Analyst Ratings (STLN)
Wall Street analysts rate STLN "Buy" based on 5 analysts, with a mean price target of USD 9.4 (range USD 8–11), per Nexqual as of October 29, 2026 at 06:21 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 9.4 |
| High Target | USD 11 |
| Low Target | USD 8 |
| Buy / Hold / Sell | 5 / 0 / 0 |
Earnings (STLN)
| Next Earnings Date | 2026-11-05 |
|---|---|
| Revenue Estimate | $168.69M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.08 vs est -0.06 ▼ miss |
| 2026-03-31 | USD -0.02 vs est -0.09 ▲ beat |
| 2025-12-31 | USD -0.06 vs est -0.09 ▲ beat |
| 2025-09-30 | USD -0.14 vs est -0.11 ▼ miss |
Source: Nexqual, October 29, 2026 at 06:21 UTC.
Financials & Fundamentals (STLN)
| Total Revenue | $587.24M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +34.60% |
| Gross Margin | +15.69% |
| Operating Margin | -2.86% |
| Profit Margin | -6.18% |
| Current Ratio | 1.36 |
| Total Cash | $41.09M |
| Total Debt | $104.79M |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | -$3.29M (-0.6% of revenue) |
Source: Nexqual, October 29, 2026 at 06:21 UTC.
Financial Health Score (STLN)
Nexqual rates The Oncology Institute, Inc.'s overall financial health "Weak" across five dimensions, as of October 29, 2026 at 06:21 UTC.
| Growth | Strong — Revenue +35% YoY (latest Q) |
|---|---|
| Profitability | Weak — Gross margin 16%, operating -4% (last 12 months) |
| Balance Sheet | Mixed — $41M cash vs $105M debt |
| Cash Flow | Weak — FCF negative: -$3M (last 4 quarters to Jun 2026, SEC), burning cash |
| Efficiency | Critical — ROE not meaningful (negative equity); ROA -20.4% (last 4 quarters, SEC) |
Ownership (STLN)
| Insider Ownership | +17.83% |
|---|---|
| Institutional Ownership | +46.52% |
| Shares Outstanding | 101.92M |
| Float | 88.89M |
| Short % of Float | +7.30% |
Source: Nexqual, October 29, 2026 at 06:21 UTC.
Leadership (STLN)
The Oncology Institute, Inc. is led by Daniel Virnich FACHE, CEO & Executive Director, per Nexqual as of October 29, 2026 at 06:21 UTC.
| CEO & Executive Director | Daniel Virnich FACHE |
|---|---|
| Chief Financial Officer | Robert Carter |
| Senior Vice President of Finance | Stephen Cella |
Major Backers & Investors (STLN)
Notable institutional backers of The Oncology Institute, Inc. include Deerfield Management Company, L.P, Josh Arnold Investment Consultant, Llc, Goldman Sachs, according to Nexqual as of October 29, 2026 at 06:21 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Deerfield Management Company, L.P | 3.36% |
| Josh Arnold Investment Consultant, Llc | 2.46% |
| Goldman Sachs | 1.74% |
| Wexford Capital LP | 1.71% |
| Fidelity | 1.67% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 4.75% |
| Vanguard Group | 3.27% |
| Geode Capital | 1.9% |
| State Street | 1.55% |
| Nuveen | 1.41% |
Source: Nexqual, October 29, 2026 at 06:21 UTC.
From The Oncology Institute, Inc.'s Latest SEC 10-K Filing (filed 2026-03-12)
Key Strengths & Strategy (as disclosed to the SEC)
- Our business is focused on caring for adult and senior populations with medical oncology and related care needs, including members of MA plans run by private insurance companies on behalf of the Centers for Medicare and Medicaid Services, or CMS, as well as traditional FFS Medicare, Medicaid, other government healthcare programs and commercial insurance populations.
- Some of the biggest and most respected names in healthcare contract with the TOI PCs to provide oncology care to their members, including Anthem, CareMore Health, Heritage Provider Network and Optum Care.
- In the United States, numerous federal and state laws and regulations, including data breach notification laws, health information privacy and security laws, including HIPAA, and federal and state consumer protection laws and regulations (e.g., Section 5 of the Federal Trade Commission ("FTC") Act, that govern the collection, use, disclosure, and protection of health-related and other personal information could apply to our operations or the operations of the TOI PCs.
- We generate these referrals based on the reputation of our doctors and our platform within the communities we serve, as well as our active and direct referrer education efforts.
Partnerships
- In the wake of the Executive Orders and related executive initiatives, a number of pharmaceutical manufacturers have announced new or expanded direct-to-consumer offerings with discounted prices and/or reached agreement with the federal government regarding discounted pricing for drugs, including prices for Medicaid drugs and newly launched products.
- We have entered into a management services agreement with each of the TOI PCs, which are entirely physician owned.
Legal & Regulatory Risks (Item 1A, quoted)
- Our managed clinics and the TOI PCs providing professional services at such clinics may become subject to medical liability claims, which could have a material adverse impact on our business.
- Our managed clinics and the TOI PCs may be subject to third-party payor audits, which, if adversely determined against us or the TOI PCs, may have a material effect on our results of operations and financial condition.
- We are subject to extensive fraud, waste, and abuse laws that may give rise to federal and state audits, investigations, lawsuits and claims against us, the outcome of which may have a material adverse effect on our business, financial condition, cash flows, or results of operations.
- We may not be able to utilize a portion of our NOLs to offset future taxable income for U.S. federal income tax purposes, which could adversely affect our net income and cash flows.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| INNV | InnovAge Holding Corp. | USD 9.1 | ▼ 0.22% |
| USPH | U.S. Physical Therapy, Inc. | USD 85.32 | ▼ 2.31% |
| NUTX | Nutex Health Inc. | USD 212.63 | ▲ 2.1% |
| PNTG | The Pennant Group, Inc. | USD 42.16 | ▲ 1.18% |
| AGL | agilon health, inc. | USD 91 | ▲ 0.39% |
| SNDA | Sonida Senior Living, Inc. | USD 33.6 | ▲ 2.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 06:21 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt